Tesamorelin is a stabilized analogue of GHRH that has received FDA approval for HIV-associated lipodystrophy. It is particularly effective at reducing visceral adipose tissue (VAT) – the dangerous fat surrounding internal organs – with significant benefits for metabolic health and body composition.
Key Benefits
- FDA-approved for visceral fat reduction
- Significant reduction in abdominal and visceral adipose tissue
- Improved lipid profiles and metabolic markers
- Increased IGF-1 levels
- Enhanced body composition without significant androgenic effects
